The city of Fayetteville, North Carolina, currently has 4 active clinical trials seeking participants for NASH - Nonalcoholic Steatohepatitis research studies.
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Recruiting
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/28/2024
Locations: Akero Clinical Study Site, Fayetteville, North Carolina
Conditions: NASH/MASH, NAFLD/MASLD
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Cumberland Research Associates, Fayetteville, North Carolina
Conditions: NASH - Nonalcoholic Steatohepatitis
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/10/2024
Locations: Akero Clinical Study Site, Fayetteville, North Carolina
Conditions: NASH With Fibrosis, MASH With Fibrosis
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH)
Recruiting
This is a safety study to evaluate BOS-580 administered subcutaneously over 12 weeks in Part A or 24 weeks in Part B.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/04/2024
Locations: Coastal Research Institute, LLC, Fayetteville, North Carolina
Conditions: Nonalcoholic Steatohepatitis (NASH)